TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2

TuHURA Biosciences, Inc./NV

2025-Q1 EPS reported -$0.15

Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).
Raised $36M in 2024; cash expected to fund operations through late Q4 2025.
Phase 3 IFx-2.0 trial for MCC under SPA with FDA; enrollment targeted Q2 2025 (partial clinical hold on CMC).
Acquisition of Kineta's VISTA antibody KVA12123 targeted to close Q2 2025.
2025 milestones include Phase 2 VISTA trial in AML; novel bi-specific ADC platform advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.